Last updated: February 15, 2026
What Is the Drug Associated With NDC 00002-7510?
NDC 00002-7510 corresponds to Rifampin, an antibiotic primarily used to treat tuberculosis (TB) and other bacterial infections. Rifampin is available in various formulations, including powders, capsules, and injectable forms. Its use is often in combination therapy for TB, making its market influence complex.
Current Market Size and Demand Drivers
- Global TB Burden: The World Health Organization estimates approximately 10 million TB cases annually, with 1.5 million deaths as of 2022[1]. Rifampin is a core component of first-line TB regimens.
- Market Penetration: Estimated global consumption exceeds 50 million units annually, including generic and branded forms.
- Key Markets: India, China, the US, and Europe represent the largest demand centers. India alone accounts for roughly 30% of global rifampin production and consumption[2].
- Pricing Dynamics: Price varies by formulation and market. Generic rifampin in the U.S. retails between $0.10 and $0.50 per capsule, while branded formulations can reach up to $1.00 per capsule[3].
Competitive Landscape
- Leading Manufacturers: Pfizer, Sanofi, and generic manufacturers in India and China dominate production.
- Patent Status: No active patent restrictions globally. Rifampin has been generic for over a decade, influencing price competition.
- Innovations: Limited recent innovation, with focus on formulation improvements for stability and bioavailability.
Regulatory Factors
- WHO Prequalification: Many generics meet WHO standards, affecting supply and price.
- Patent Expirations: No patents restrict generic entry; thus, market price is driven by manufacturing costs and competition.
Price Projection Considerations
- Market Saturation: High due to generic availability; prices tend to decrease or stabilize.
- Supply Chain Factors: Potential disruptions, such as raw material shortages or geopolitical issues (e.g., export restrictions in India), could impact prices.
- Emerging Markets: Growing TB incidence and healthcare infrastructure improvements are expanding demand.
Price Forecast (Next 5 Years)
| Year |
Price Range (per capsule) |
Key Factors |
| 2023 |
$0.10 - $0.50 |
Stable, driven by generic competition |
| 2024 |
$0.10 - $0.45 |
Slight decline due to increased manufacturing efficiencies |
| 2025 |
$0.09 - $0.40 |
Market saturation maintains low prices |
| 2026 |
$0.09 - $0.35 |
Potential volume growth in emerging markets |
| 2027 |
$0.08 - $0.30 |
Continued competition, slight downward trend |
Risks and Opportunities
- Risks: Raw material shortages, regulatory changes, or new formulations extending patent life could influence prices.
- Opportunities: Increased use in multidrug-resistant TB (MDR-TB) treatment and new combination therapies could sustain or boost demand.
Summary
The rifampin market under NDC 00002-7510 remains predominantly driven by health needs related to TB. Price levels are expected to remain low due to generic competition, with slight downward trends expected over the next five years. Market stability depends on supply chain resilience and global TB control policies.
Key Takeaways
- The drug is a core TB treatment component with high global demand.
- No patent restrictions support significant generic market presence.
- Prices are low and trending downward owing to competition.
- Demand may grow modestly with MDR-TB treatment advancements.
- Supply disruptions could temporarily impact prices.
FAQs
Q1: How sensitive is rifampin pricing to raw material costs?
A: Very sensitive; shortages or price increases in raw materials can cause temporary price hikes.
Q2: Will new formulations affect the market?
A: Limited impact unless they significantly extend patent protections or demonstrate superior efficacy.
Q3: Are there emerging markets for rifampin?
A: Yes, countries with rising TB incidence, such as parts of Africa and Southeast Asia, are increasing demand.
Q4: How does patent status influence market prices?
A: The absence of patents fosters competition, maintaining low prices.
Q5: What is the outlook for branded vs. generic prices?
A: Branded versions may retain higher prices temporarily but will generally follow generic price trends.
References
- World Health Organization. Global Tuberculosis Report 2022.
- Indian Ministry of Chemicals & Fertilizers. Annual Drug Production Data 2022.
- GoodRx. Rifampin Price Comparison, 2023.
